- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper proposes CSIL for drug–drug interaction (DDI) event prediction between chiral drugs. The model combines a shared atom encoder, motif representations, and a chirality branch using explicit stereochemical descriptors. Representations are aggregated across conformers and candidate configurations, followed by cross-drug attention and classification. CSIL achieves the best reported mean in 22 of 24 task–metric combinations.
Critical strengths
Separating unseen forms of known parent structures from unseen-parent generalization is a useful direction for evaluating stereochemistry-aware DDI prediction. This could expose limitations that conventional drug-pair splits do not directly address. The chirality-branch ablation also shows improvements in several generalization metrics, supporting an incremental benefit within CSIL.
Critical weaknesses
-
The evaluation provides limited direct evidence for configuration-dependent DDI prediction. The dataset is derived by selecting DrugBank interactions between chiral drugs, but this does not necessarily demonstrate that the benchmark tests differences caused by configuration. Neither the main text nor Appendix A.2 quantifies matched examples in which different configurations of the same parent interact with the same partner, particularly examples with different event labels. Performance on this subset is also not reported, leaving some uncertainty about how directly the evaluation supports the paper's central motivation.
-
The chirality-specific contribution is difficult to assess without clearer feature definitions and ablation details. Section 4.2 identifies the categories of chirality descriptors, but I could not locate a complete specification of the initial atom features, bond/distance encodings, or the construction of the signed-volume and determinant features in the main text or appendix. Moreover, Eq. (4) introduces chirality-related role embeddings before the shared atom encoder. It is unclear whether these embeddings or other stereochemical inputs remain in the "w/o chirality branch" variant.
Comparing Tables 1 and 2, the variant without the chirality branch achieves competitive performance to the best external baseline, based on reported means. The remaining architecture is therefore already competitive without the dedicated branch. It would be helpful to clarify whether the chirality branch can also improve other DDI models.
Questions for authors
-
How many matched examples contain different fully specified configurations of the same parent paired with the same partner, and how often do their event labels differ? How does CSIL perform on these cases, particularly those with different event labels?
-
What are the exact attributes, extraction tools, and encodings used for the initial atom and edge features? How are CIP assignments, signed chiral volumes, and determinant features constructed, including neighbor ordering and sign conventions? In the chirality-branch ablation, are the role embeddings in Eq. (4), any stereochemical atom features, and candidate-configuration processing retained?
-
What makes motif-level modeling particularly useful for the proposed chirality mechanism? Table 2 gives a slightly better F-rank to "w/o motif" (4.396) than to "w/o chirality" (4.479), although the full model is better than both (2.021); this comparison alone establishes neither motif redundancy nor chirality-specific necessity.
-
Does the model support an empty chiral-center set? If so, how are the chirality token and the retained feature in Eq. (12) handled? If results are available, how does CSIL behave on the full DrugBank dataset or excluded pairs, separating achiral–achiral from mixed chiral–achiral cases?
-
The reference to Chawla (2025) appears to omit the coauthors. Could you please check the author list against the following record?
Chawla S, Gupta R, Jha SK, Shamim, Kashid S, Jha KT. Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and Conformational Isomers. Med Chem. 2025 Oct 3. doi: 10.2174/0115734064366389250923044201. Epub ahead of print. PMID: 41051049.
5 comments
Thank you for the response. I still have two concerns: (1) If the blind inputs no longer distinguish the two configurations, how does this variant achieve a pair accuracy of 0.624 on enantiomer pairs with different labels? (2) I understand that motif and chirality representations can be complementary. However, the reported gains could also be interpreted as benefits of a more general "motif-structural interaction learning framework." The current evidence does not yet clearly establish the distinctive benefit of the proposed chirality module.
Thank you for your response and valuable insights.
Q: The non-zero score of the configuration-blind variant; the distinctive benefit of the chirality module
A (1). Our wording was imprecise and we have corrected it. The variant merges the CIP R/S one-hots and zeroes the signed chirality channels, but it does not give the two members identical inputs, because each drug's conformers are embedded independently with a seed derived from its own identifier: even the best-matching conformer pair differs in pairwise heavy-atom distances by up to 2.42 Å. These residuals are parity-even and carry no R/S information, but they identify the molecule, and each member is seen in training against many other partners, so 0.624 is a memorisation floor rather than configuration reading. The bound of zero we had in mind holds for exactly mirrored inputs, which we now verify: under a parity transform of one member's own conformers the blinded inputs are bit-identical, so the variant returns the same logits for a molecule and its mirror image for any weights, whereas CSIL changes its predicted class in 33 of 152 cases (Figure 3d). Our conclusion rests on the paired contrast on the same pairs (+0.128 pair accuracy, p = 0.001) and on CSIL discriminating 0.768 of the label-discordant pairs against 0.012 of the label-concordant ones, not on the ablated arm's absolute level.
A (2). The ablated variant is precisely this control, which we had not made clear: it keeps the motif branch, the chiral branch, the cross-attention, the gated aggregation and the chirality token at an identical parameter count and training protocol, neutralising only the configuration-bearing inputs, unlike the w/o chirality row of Table 2, which also removes the module. The two arms are indistinguishable in overall accuracy (0.970 vs 0.972), so the general framework accounts for the general classification performance, while the entire difference is confined to the 125 enantiomer pairs whose labels differ (+12.8 points) and is absent on diastereomer pairs, whose configurations are separated by reflection-invariant distances. A general-framework benefit cannot be selective in this way, and Appendix A.10 adds the converse, where the chirality branch alone improves F1 on all four tasks. We have tightened Section 5.4 accordingly: the module is not claimed to explain the overall margin over the baselines, but to supply configuration sensitivity the motif framework alone does not provide. The module operates on chiral-centre descriptors and a drug-level token, so it is not specific to this backbone.
We have revised Appendix A.11 to define the variant channel by channel, to state that it is capacity-matched, to explain its non-zero score on enantiomer pairs as a memorisation floor and to report the parity-transform check, and Section 5.4 to use the same description of the variant and to attribute the overall classification performance to the general framework and the configuration-dependent behaviour to the chirality module.
Thank you for your valuable comments.
Q1: Matched Stereoisomer Statistics and Performance
A: (1) Requiring the same parent, partner drug and #Drug1/#Drug2 position, CDDI has 4,903 matched pairs of fully specified configurations (9,690 records), of which 491 (10.0%) carry different event labels: 125 of 2,642 enantiomer pairs and 366 of 2,261 diastereomer pairs. Table 4 pools the two positions, hence its 18.1%. We have added this to Appendix A.2.
(2) Both members of a pair fall in the same fold, so neither label is seen during training; we repeated the five folds with a variant whose inputs no longer distinguish the two configurations ("blind"). On the 125 enantiomer pairs with different labels, CSIL gets both members right in 75.2% of pairs against 62.4% for the blind variant, and separates the two members in 76.8% of them against 1.2% of the 4,412 pairs whose labels agree. Diastereomer pairs show no such gap, so only enantiomers read as evidence on configuration, and a quarter of them are still missed. The per-subset results are reported in the new Appendix A.11 (Table 11), summarized at the end of Section 5.4.
Q2: Feature Construction and Chirality Ablation Details
A: (1) Input features. All features come from RDKit on heavy-atom graphs with ETKDGv3 conformers: 47-dim atom and 29-dim edge features over bonded atoms and the 16 nearest atoms within 4.5 Å. We have added Appendix A.6, cited in Section 4.2, which lists every feature with its dimension, encoding and RDKit function in Table 6(a)(b).
(2) Chirality descriptors. R/S labels come from RDKit's
FindMolChiralCenters. For each center, three difference vectors over its CIP-ranked neighbors form a matrix M with unit-length columns; detM flips sign under reflection and is positive for R in 98.9% of centers, and the signed chiral volume is v=s⋅min(∣detM∣,1) with s=±1 for R/S. We have given the full construction in Appendix A.6, with all 20 descriptors in Table 6(c).(3) Chirality-branch ablation. The variant removes only the branch (Xχ, chiral cross-attention, gated aggregation, stereo-state embedding, chirality token) and keeps the role embeddings, stereochemical atom and edge features, and candidate configurations, so it measures the branch rather than stereochemical information as a whole. We have stated this in Section 5.4.
Q3: Motif-Level Contribution to Chirality Modeling
A: We have clarified that F-rank is the Friedman mean rank over 24 task-metric combinations, where a lower value indicates better overall performance rather than the importance of an individual component. Each variant in Table 2 removes one component and retains the rest. The motif and chirality branches are complementary, the former capturing structural context and the latter configuration-sensitive information, so the small F-rank gap between w/o motif and w/o chirality does not make either branch the more important one.
To separate their contributions, we have added component-wise addition experiments in Appendix A.10: starting from a common base model, each component is added independently. Both branches improve F1 on all four tasks, and the full model attains the highest F1 on every task and the best overall F-rank, which further supports the complementary contributions of motif and chirality modeling to CDDI prediction.
Q4: Empty Chiral-Center Handling and Non-Chiral DDI Evaluation
A: CSIL needs no architectural change for an empty chiral-center set. With a clamped normalizer, the gated aggregation returns a zero chirality vector in Eq. (9). The chirality token fed to Eq. (12) is the layer norm of that vector plus a learned embedding of the drug's chirality state, which the original text omitted. For a drug with no chiral centers the token therefore reduces to a constant, the layer norm of the embedding for the unspecified state. Achiral drugs are thus unmasked and distinguished by their motif tokens.
Re-adding their interactions (full DrugBank: 1,136,882 DDIs, 3,604 drugs), we compared CSIL with MSHGCL, the best-ranked baseline in Table 1, under Task 1 with five-fold CV on identical folds. CSIL exceeds 97.9% accuracy in every pair group and outperforms MSHGCL on all metrics for chiral–chiral pairs; on mixed and achiral–achiral pairs the two models are within one standard deviation. The per-group accuracy and F1 are reported in the new Appendix A.7 (Table 7).
We have defined the chirality state (Section 3.2) and the chirality token (Section 4.3), described the empty-set case (Section 4.2), rewritten Eq. (12) with the chirality token (Section 4.4), and summarized the full DrugBank results at the end of Section 5.2.
Q5: Correction of Reference Author List
A: We apologize for the incomplete author information. We have checked the author list against the provided record and corrected the reference to list all coauthors in the revised PDF. We thank the reviewer for catching this.